Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
O-1918 is a synthetic small molecule compound structurally related to cannabidiol. It acts as an antagonist at the G protein-coupled receptors GPR18 and GPR55, which are former orphan receptors now recognized as part of the extended endocannabinoid system. These receptors are implicated in mediating non-CB1 and non-CB2 cannabinoid effects. O-1918 is widely used in research to study the pharmacology of these atypical cannabinoid targets and their physiological roles. Additionally, electrophysiological studies have shown that O-1918 is a potent inhibitor of large-conductance calcium-dependent potassium (BKCa) channels[1][3][7]. There is interest in its potential for modulating vascular tone and energy metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on O-1918.